Xenetic Biosciences and Periness Enter Clinical Study Agreement to Advance DNase 1 Platform for Large B-Cell Lymphoma Treatment

Xenetic Biosciences, Inc., a biopharmaceutical company pioneering in immuno-oncology, has entered into a clinical study agreement with Periness Ltd. to explore the combination of DNase 1 and anti-CD19 CAR T-cell therapy for patients with large B-cell lymphoma. This strategic collaboration aims to advance research into a promising new approach for enhancing cancer immunotherapy outcomes. The upcoming exploratory clinical study will be led by Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at Tel Aviv Sourasky Medical Center. Study Focus: Safety, Efficacy & CAR T Performance The clinical study is designed to assess two primary objectives: Tolerability and safety of DNase 1 as an adjuvant therapy when combined with anti-CD19 CAR T-cells in patients with stable or responding large B-cell lymphoma. Efficacy, measured by response rate post CAR T-cell infusion, overall survival, and duration of therapeutic response. The trial includes a translational component, examining the persistence and expansion of anti-CD19 CAR T-cells and associated biomarker responses critical for understanding long-term immune functionality.

• Role of Periness As part of the agreement, Periness Ltd. will oversee:
• Regulatory approval processes
• Study operations
• Investigator management

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting Periness brings relevant experience, having conducted DNase 1-based clinical studies as adjunctive treatment in pancreatic carcinoma, locally advanced, and metastatic solid tumors in Israel. Expert Insights Dr. Alexey Stepanov, Ph.D., Institute Investigator at the Scripps Research Institute and member of Xenetic’s scientific steering committee, highlighted the scientific rationale behind the study: “Our preclinical data show that degrading neutrophil extracellular traps (NETs) with DNase 1 prevents premature CAR T-cell exhaustion and enhances their function. When combined with anti-CD19 CAR T-cells, DNase 1 significantly reduced tumor burden and improved survival rates compared to CAR T-cell monotherapy in multiple experimental models.” Company Perspective James Parslow, Interim CEO and CFO of Xenetic, expressed optimism about the study’s potential: “We are encouraged by the steady progress of our DNase 1 program. This agreement marks a meaningful step in exploring its utility across oncology indications. We look forward to generating more data to unlock the full therapeutic value of DNase 1.” With this collaboration, Xenetic and Periness are poised to advance the next generation of immunotherapy solutions for lymphoma and possibly other cancers in the near future. Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: [email protected]